Supernus Pharmaceuticals, Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 19 October 2026: press release. The quarter’s numbers.

Key takeaways

CEO and CFO host the call: Khattar and Dec host the call and webcast at 4:30 p.m. ET to discuss the results. Source
Questions follow prepared remarks: The call opens with management's prepared remarks and discussion of business results, then takes questions. Source
Live webcast on investor site: The live webcast is listed in the Events & Presentations section of the Company's Investor Relations website. Source
Filing announces date only: The exhibit is titled as an announcement of third quarter 2026 results and the conference call. It carries no quarterly revenue, earnings or guidance figures. Source
Prior release covered second quarter: The previous release, dated August 3, 2026, reported second quarter 2026 results. The current filing does not restate those figures.

Call format and hosts

CEO and CFO host the call: Khattar and Dec host the call and webcast at 4:30 p.m. ET to discuss the results. Source
Questions follow prepared remarks: The call opens with management's prepared remarks and discussion of business results, then takes questions. Source

Registration and dial-in

Pre-registration before the call: Participants can pre-register before the call and then receive a dial-in number with a personalized conference code. Source
Dial in early: Participants are asked to dial in 15 minutes before the start time. Source

Webcast and replay access

Live webcast on investor site: The live webcast is listed in the Events & Presentations section of the Company's Investor Relations website. Source
Replay posted after the call: A replay is to be posted on the Investor Relations website following the live call. Source
Webcast kept for 60 days: The webcast will remain on the Company's website for 60 days after the live call. Source

Company focus and portfolio

CNS-focused biopharmaceutical company: The company describes itself as focused on developing and commercializing products for central nervous system diseases. Source
Approved treatment areas listed: The company lists approved treatments for ADHD, Parkinson's dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Source
Novel candidates in development: The company states it is developing a broad range of novel product candidates for CNS disorders. Source

Speakers and contacts

CEO and CFO named as contacts: Jack A. Khattar is listed as President and CEO and Timothy C. Dec as Senior Vice President and CFO. Source
Investor contact at ICR Healthcare: Peter Vozzo of ICR Healthcare is listed as the investor contact. Source

Scope of this filing

Filing announces date only: The exhibit is titled as an announcement of third quarter 2026 results and the conference call. It carries no quarterly revenue, earnings or guidance figures. Source
Prior release covered second quarter: The previous release, dated August 3, 2026, reported second quarter 2026 results. The current filing does not restate those figures.

Coming up, as management said on 19 October 2026

Results and call on October 29: The company will report third quarter 2026 results after the market closes on October 29, 2026, with the call at 4:30 p.m. ET. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.

As filed with the SEC

Open the filing on EDGAR

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

ROCKVILLE, Md., October 19, 2026 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Thursday, October 29, 2026, at 4:30 p.m. ET to discuss these results. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at https://ir.supernus.com/events-and-presentations.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.

For more information, please visit www.supernus.com.

Forward-Looking Statements

Forward-looking statements notice

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; the Company's ability to increase its net revenue from its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; the Company's ability to commercialize its products, the products of its subsidiaries, and products acquired through the acquisition of Sage; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange

Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

(443) 213-0505 peter.vozzo@icrhealthcare.com

Contacts
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
Peter Vozzo
ICR Healthcare